HEALTHPEAK PROPERTIES, INC. — Form 8-K

Healthpeak reported Q3 2026 FFO as Adjusted of $0.44/share and raised full-year 2026 FFO as Adjusted guidance to $1.76–$1.78/share (midpoint +$0.02 vs. prior August guidance). Key drivers: Lab occupancy increased 270 bps since year-end 2025; Janus Living (69% owned) reported 78% revenue and 101% Adjusted EBITDAre growth YoY; company acquired/contracted ~$233M of life science buildings (510k sq ft) and one $38M outpatient medical property; sold 49% interest in $2.1B outpatient medical joint venture to Brookfield for ~$1.025B; entered $500M unsecured term loan facility. Net Debt to Adjusted EBITDAre: 4.7x. Diluted EPS guidance lowered to $0.39–$0.41 (down $0.10 midpoint) due to depreciation from Janus acquisitions, but this does not impact FFO measures.